Nektar Therapeutics (NKTR) shares are trading at lower $16.48 and the avg recommendation for the stock is Moderate Buy.
To add more color to this target, the company’s high over the last year is $28.60 and the low is $13.63. Over the last 52 weeks, NKTR is down -6.89% while the S&P 500 is up 11.51%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
In the last quarter, NKTR reported a profit of $43.07 million. Nektar Therapeutics also saw revenues increase to $48.85 million. In addition, NKTR has free cash flow of -$165.57 million as of 06-2020. The company’s EBITDA came in at -$75.3 million which compares well with its peers.
NKTR Return on Equity (ROE) is -31.60%, and its Return on Assets is -22.80%. All told, it is clear that, NKTR needs to be on your watchlist.
Find out when NKTR reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. NKTR has a short ratio of 25.94 and outstanding shares of 178.33M.
NKTR has seen increased volume after this news and investors are putting their support behind the value proposition. Traders will also note the company’s earnings per share came in at -2.44. Nektar Therapeutics NKTR also noted assets of $1.59 billion at the end of the last quarter. Investors should also keep an eye on sector updates as NKTR has historically followed its peers on positive news.
All told, Nektar Therapeutics NKTR has strung together solid data and demonstrated underlying fundamentals. At its current valuation, NKTR represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.
Nektar Therapeutics NKTR is now commanding a market cap of 2.89B and a float of 177.51M. NKTR is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of NKTR stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in NKTR, either long or short, and we have not been compensated for this article.